Literature DB >> 1633069

Enhancement of the oral absorption of cyclosporin in man.

J Drewe1, R Meier, J Vonderscher, D Kiss, U Posanski, T Kissel, K Gyr.   

Abstract

1. The oral absorption of cyclosporin from three new semi-solid oral formulations was compared with the standard soft gelatine preparation in twelve healthy male volunteers. One formulation was based on a solid micellar solution, while the other two, with different in vitro release properties, were based on a microemulsion principle. 2. The results showed that the solid micellar solution and the faster releasing microemulsion formulation increased the extent of absorption on average by 45.2 and 49.0%, respectively, compared with the reference soft gelatine capsule.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633069      PMCID: PMC1381376          DOI: 10.1111/j.1365-2125.1992.tb04108.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  High-fat meals increase the clearance of cyclosporine.

Authors:  S K Gupta; L Z Benet
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

2.  Single dose pharmacokinetics of ciclosporin and its main metabolites after oral ciclosporin as oily solution or capsule.

Authors:  J S Bleck; B Nashan; U Christians; R Schottmann; K Wonigeit; K F Sewing
Journal:  Arzneimittelforschung       Date:  1990-01

3.  The effect of vehicle on the oral absorption of cyclosporin.

Authors:  A Johnston; J T Marsden; K K Hla; J A Henry; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

4.  On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers.

Authors:  J P Reymond; J L Steimer; W Niederberger
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

5.  The effects and side effects of cyclosporine: relationship to drug pharmacokinetics.

Authors:  P A Keown; C R Stiller; A L Laupacis; W Howson; R Coles; M Stawecki; J Koegler; G Carruthers; N McKenzie; N R Sinclair
Journal:  Transplant Proc       Date:  1982-12       Impact factor: 1.066

6.  Pharmacokinetic criteria for the evaluation of retard formulations.

Authors:  J Meier; E Nüesch; R Schmidt
Journal:  Eur J Clin Pharmacol       Date:  1974-10-04       Impact factor: 2.953

7.  The effect of food on cyclosporine absorption.

Authors:  R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

8.  The absorption site of cyclosporin in the human gastrointestinal tract.

Authors:  J Drewe; C Beglinger; T Kissel
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

9.  Small-bowel length and the dose of cyclosporine in children after liver transplantation.

Authors:  P F Whitington; J C Emond; S H Whitington; C E Broelsch; A L Baker
Journal:  N Engl J Med       Date:  1990-03-15       Impact factor: 91.245

10.  Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing.

Authors:  A Lindholm; S Henricsson; M Lind; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more
  5 in total

Review 1.  A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features.

Authors:  S Friman; L Bäckman
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Clinical studies with oral lipid based formulations of poorly soluble compounds.

Authors:  Dimitrios G Fatouros; Ditte M Karpf; Flemming S Nielsen; Anette Mullertz
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

4.  Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion.

Authors:  A K Trull; K K Tan; L Tan; G J Alexander; N V Jamieson
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

5.  Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing.

Authors:  Krishna Devarakonda; Joris Vandenbossche; Ute Richarz
Journal:  Springerplus       Date:  2013-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.